![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Kessler Medical Rehabilitation Research Center Kessler Foundation UCB |
---|---|
Information provided by: | Kessler Medical Rehabilitation Research Center |
ClinicalTrials.gov Identifier: | NCT00227461 |
The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.
Condition | Intervention | Phase |
---|---|---|
Aphasia Stroke Amnesia |
Drug: Levetiracetam |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-Stroke Patients. |
Estimated Enrollment: | 50 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
patients are randomized to BABA or ABAB design of receiving drug vs. off-drug period
|
Drug: Levetiracetam
patients are randomized to BABA or ABAB design of receiving drug vs. off-drug period
|
In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Siby Varughese, RN | 973 324-3564 | svarughese@kmrrec.org |
Contact: Anna Barrett, MD | 973 324-3569 | abarrett@kmrrec.org |
United States, New Jersey | |
KMRREC | Recruiting |
West Orange, New Jersey, United States, 07052 | |
Contact: Jenny Masmela, BA 973-324-3564 jmasmela@kmrrec.org | |
Contact: Milda Woods 973 243-6978 mwoods@kmrrec.org |
Principal Investigator: | Anna Barrett, MD | KMRREC |
Responsible Party: | KMRREC ( A. Barrett, Principal Investigator ) |
Study ID Numbers: | AMBarrett1, none applicable |
Study First Received: | September 26, 2005 |
Last Updated: | October 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00227461 |
Health Authority: | United States: Food and Drug Administration |
Aphasia Stroke |
Speech Disorders Cerebral Infarction Aphasia Stroke Vascular Diseases Central Nervous System Diseases Language Disorders Brain Diseases Cerebrovascular Disorders Memory Disorders Cognition Disorders |
Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Neurologic Manifestations Etiracetam Dementia Neurobehavioral Manifestations Amnesia Communication Disorders Delirium |
Nootropic Agents Therapeutic Uses Nervous System Diseases Cardiovascular Diseases |
Central Nervous System Agents Pharmacologic Actions Anticonvulsants |